Skip to Content

Fexapotide triflutate Approval Status

FDA Approved: No
Generic name: fexapotide triflutate
Previous Name: NX-1207
Company: Nymox Pharmaceutical Corporation
Treatment for: Benign Prostatic Hyperplasia

Fexapotide triflutate is an injectable pro-apoptotic agent in development for the treatment of benign prostatic hyperplasia.

Development Status and FDA Approval Process for fexapotide triflutate

DateArticle
Feb  5, 2018Nymox Announces US NDA for Fexapotide for BPH
Jan 30, 2018Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology
Apr 16, 2013New Study Supports Favorable Sexual Function Profile for Nymox's NX-1207 for Prostate Enlargement
Feb 19, 2013Nymox Announces Positive Immunogenicity Results for NX-1207 BPH Program
Jan 23, 2013Nymox Announces New Positive Results in Phase 3 Repeat Injection Study of NX-1207 for BPH
Oct  9, 2012Nymox NX-1207 Prostate Cancer Trial Receives Second Positive Interim Safety Review From Independent Data Monitoring Committee
Jul 19, 2012Favorable July 12 Safety Monitoring Committee Meeting for Nymox Pivotal Phase 3 NX-1207 Trials
Jul 19, 2012Favorable July 12 Safety Monitoring Committee Meeting for Nymox Pivotal Phase 3 NX-1207 Trials
Feb 15, 2012Nymox Announces Current Safety Monitoring Committee Results and Update For Phase 3 NX-1207 Trials
Nov 22, 2011Nymox Provides Safety Monitoring Committee Results and Update For Pivotal Phase 3 NX-1207 Trials
Oct 19, 2011New Positive Data on NX-1207 Presented at Symposium at American Urological Association Meeting October 19
Apr 14, 2011Nymox Announces New Positive Long-Term 39-45 Month Follow-Up Results From NX02-0016 U.S. Study of NX-1207 for BPH
Mar 17, 2011Nymox Announces Positive New Results in 7 Year Study of NX-1207 for Benign Prostatic Hyperplasia
Feb  3, 2011Safety Monitoring Committee Meeting For Nymox Pivotal Phase 3 NX-1207 Trials Indicates Favorable Safety Profile
Jul 29, 2010Nymox Reports Safety Monitoring Committee Findings For Pivotal Phase 3 NX-1207 Trials
May  5, 2010Nymox Announces Positive New Results in 6 Year Study of NX-1207 for Benign Prostatic Hyperplasia
Nov 23, 2009Nymox Releases Positive New Clinical Trial Data on Durability of Benefits for Early Responders to Company?s BPH Drug NX-1207
Oct  5, 2009Nymox Announces New Pooled Analysis Confirms 12 Month Benefit of NX-1207 Treatment for BPH
Aug 26, 2009Nymox's NX-1207 Shows Major Effect on Liver Cancer
Jan 13, 2009Nymox Releases Positive New Clinical Trial Data on Durability of Response Rates to Company’s BPH Drug NX-1207
Dec 19, 2008Nymox NX-1207 Successful Clinical Trial Results Featured in Urology Times
Dec 16, 2008Nymox Releases New Study Data from U.S. Study of NX-1207 for Benign Prostatic Hyperplasia Which Shows Significantly Less Interruption of Sleep For Men Given Nymox Drug
Dec  3, 2008Nymox Reports Positive New Clinical Trial Data on Improvement in Urinary Urgency and Frequency Symptoms in Patients on NX-1207 Drug for Prostate Enlargement
Oct 30, 2008Nymox NX-1207 Data Presented Today at American Urological Association Meeting in Monterey
Oct 28, 2008Recent Clinical Trial data for Nymox NX-1207 Drug to Be Presented at American Urological Association Meeting in Monterey on Thursday
Oct 10, 2008Nymox NX-1207 Successful Clinical Trial Results Featured in Urology Times
Sep 25, 2008Nymox NX-1207 Data Presented Today at American Urological Association Meeting in Chicago
Sep 23, 2008Clinical Results for Nymox BPH Drug NX-1207 to Be Presented at American Urological Association Meeting in Chicago on September 25
Sep 19, 2008Nymox NX-1207 Data Presented at American Urological Association Meetings in San Diego and Santa Ana Pueblo, New Mexico
Sep 16, 2008Clinical Trial Results for NX-1207 to be Presented at Second AUA Meeting in San Diego on September 18
Sep 11, 2008Clinical Trial Investigators to Present New Data Next Week on Nymox's NX-1207 For Benign Prostatic Hyperplasia
Jun 24, 2008Independent Clinical Trial Investigators To Present New Data onNymox's NX-1207 Drug in Development For Benign ProstaticHyperplasia
May 28, 2008Nymox Reports Significant Long-Term Improvement in BPH SymptomsAfter NX-1207 Treatment in New Multi-Center U.S. Study
Apr 30, 2008Nymox Announces New Positive Results at 54 Months in Long TermStudy of NX-1207 for Benign Prostatic Hyperplasia
Apr 15, 2008Nymox Nears Completion of Latest U.S. Study of NX-1207 for BenignProstatic Hyperplasia
Apr  1, 2008Nymox Releases Positive New Clinical Trial Data on Response Ratesto Company's Prostate Drug NX-1207
Mar 11, 2008Nymox Releases Further Results from Latest U.S. Study of NX-1207for Benign Prostatic Hyperplasia
Mar 11, 2008Nymox Releases Further Results from Latest U.S. Study of NX-1207for Benign Prostatic Hyperplasia
Feb 20, 2008Nymox's NX-1207 Offers a New and Attractive Approach to theTreatment of Benign Prostatic Hyperplasia
Feb  6, 2008Nymox Announces Positive Results from New Multi-Center U.S. Studyof NX-1207 For BPH
Jan 17, 2008Nymox to Report Results of New Phase 2 Study of NX-1207 for BPH
Jan 16, 2008Nymox to Report Results of New Phase 2 Study of NX-1207 for BPH
Dec 12, 2007Nymox Reports Update on NX-1207 Study Results, Marketing Plans andActivities
Nov 28, 2007Nymox Announces Positive Results in New 2 Year Blinded, PlaceboControlled Study of NX-1207 for Benign Prostatic Hyperplasia
Nov 14, 2007Nymox Reports Completion of Large New 2 Year Follow-up Study ofNX-1207 for BPH
Jun 21, 2007Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.Urology Meetings
Jun 21, 2007Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.Urology Meetings
Apr 18, 2007Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207for BPH
Mar 19, 2007Nymox Announces Positive Results from Newly Completed Long-termStudy of NX-1207 for Benign Prostatic Hyperplasia
Feb 28, 2007Nymox Reports Completion of New Long-term Study of NX-1207 for BPH

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide